Dublin, Aug. 25, 2020 (GLOBE NEWSWIRE) -- The "Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Recurrent or Metastatic Head and Neck Cancer Pipeline Insight, 2020" report provides comprehensive insights of present clinical development scenario and growth prospects across the Recurrent or Metastatic Head and Neck cancer market. A detailed picture of the Recurrent or Metastatic Head and Neck cancer pipeline landscape is provided, which includes the disease overview and Recurrent or Metastatic Head and Neck cancer treatment guidelines. The assessment part of the report embraces in-depth Recurrent or Metastatic Head and Neck cancer commercial assessment and clinical assessment of the Recurrent or Metastatic Head and Neck cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals, and product development activities comprising the technology, Recurrent or Metastatic Head and Neck cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Recurrent or Metastatic Head and Neck cancer with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Recurrent or Metastatic Head and Neck cancer treatment.
- Recurrent or Metastatic Head and Neck cancer key players involved in targeted therapeutics development with respective active and inactive projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations, licensing agreement and financing details for future advancement of Recurrent or Metastatic Head and Neck cancer market.
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations, company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Recurrent or Metastatic Head and Neck cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Recurrent or Metastatic Head and Neck cancer across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Recurrent or Metastatic Head and Neck cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Recurrent or Metastatic Head and Neck cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Recurrent or Metastatic Head and Neck cancer .
Key Topics Covered:
1. Report Introduction
2. Recurrent or Metastatic Head and Neck cancer
3. Recurrent or Metastatic Head and Neck cancer Current Treatment Patterns
4. Recurrent or Metastatic Head and Neck cancer - Analytical Perspective
5. Therapeutic Assessment
6. Recurrent or Metastatic Head and Neck cancer Late Stage Products (Phase-III)
7. Recurrent or Metastatic Head and Neck cancer Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Recurrent or Metastatic Head and Neck cancer Discontinued Products
13. Recurrent or Metastatic Head and Neck cancer Product Profiles
14. Recurrent or Metastatic Head and Neck cancer Key Companies
15. Recurrent or Metastatic Head and Neck cancer Key Products
16. Dormant and Discontinued Products
17. Recurrent or Metastatic Head and Neck cancer Unmet Needs
18. Recurrent or Metastatic Head and Neck cancer Future Perspectives
19. Recurrent or Metastatic Head and Neck cancer Analyst Review
20. Appendix
21. Report Methodology
Companies Mentioned
- Aduro Biotech, Inc.
- AstraZeneca
- Merck Sharp & Dohme Corp.
- MedImmune LLC
- Dynavax Technologies Corporation
- Advaxis, Inc.
- Cue Biopharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/50n665
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900